Trump administration must defend and protect U.S. innovation

Priscilla VanderVeer   |     February 6, 2020   |   SHARE THIS

PhRMA recently submitted comments to the Office of the United States Trade Representative (USTR)’s Special 301 Report, calling on the Trump administration to defend American biopharmaceutical innovators and jobs by ending market access and intellectual property barriers in 24 leading economies around the world.

There were three key takeaways from the submission:

  • Discriminatory practices abroad free ride on American innovation and put U.S. jobs and exports at risk.

    The United States leads the world in the research and development of new medicines and vaccines, but when foreign trade barriers undervalue U.S. biopharmaceutical innovation, it threatens American jobs and exports.

  • The United States must use all available tools to ensure our trading partners honor their obligations, end these discriminatory practices and level the playing field for American inventors and workers.

    Urgent action is needed particularly to reverse compulsory licensing practices in Malaysia and to end damaging pricing policies in several markets, including Canada, Japan and South Korea.

  •  Standing up for American innovators delivers results.

    As a recent example of progress, the U.S.-China Phase One Trade Agreement includes intellectual property protections that are essential to drive and sustain biopharmaceutical innovation.

The 2020 Special 301 Report is an important opportunity to advance the Trump administration’s commitment to opening overseas markets and to ensure America’s trading partners adopt high standards of intellectual property protection and enforcement. To view PhRMA’s complete 2020 Special 301 submission, please click here.

Priscilla VanderVeer

Priscilla VanderVeer Priscilla VanderVeer Priscilla VanderVeer is a vice president, public affairs, at PhRMA. Ms. VanderVeer has more than 15 years of experience communicating important health care issues to a wide variety of audiences, including medical, health and patient advocates; policymakers and opinion-leaders; and the general public. At PhRMA, Ms. VanderVeer leads the development and execution of communications strategies and activities for the organization’s key state advocacy priorities. She lives in Annapolis, Maryland with her husband, Ken and their two dogs: Bea Arthur, a tiny 5 lb. Maltese and Henry, a slightly larger-than-average Yorkshire Terrier.

Topics: Intellectual Property, Trade

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates